minimally invasive surfactant therapy in preterm
TRANSCRIPT
![Page 1: Minimally invasive surfactant therapy in preterm](https://reader036.vdocument.in/reader036/viewer/2022081416/556c8fe9d8b42a7a738b4cf3/html5/thumbnails/1.jpg)
BMJ– FETAL & NEONATAL MEDICINEMARCH 2013
![Page 2: Minimally invasive surfactant therapy in preterm](https://reader036.vdocument.in/reader036/viewer/2022081416/556c8fe9d8b42a7a738b4cf3/html5/thumbnails/2.jpg)
Ojective : to evaluate the applicability & potential effectiveness of a technique of minimal invasive surfactant therapy in preterm infants on cpap
![Page 3: Minimally invasive surfactant therapy in preterm](https://reader036.vdocument.in/reader036/viewer/2022081416/556c8fe9d8b42a7a738b4cf3/html5/thumbnails/3.jpg)
Already known on this topic
Preterm infants managed intially on cpap will go on to require intubation because of respiratory distress related to surfactant defeciency
![Page 4: Minimally invasive surfactant therapy in preterm](https://reader036.vdocument.in/reader036/viewer/2022081416/556c8fe9d8b42a7a738b4cf3/html5/thumbnails/4.jpg)
What this study addsA technique of MIST using narrow bore
vascular catheter inserted into trachea was successfully applied by neonatal physicians at two sites
Administration of surfactantb via MIST resulted in sustained reduction in o2 requirement &decrease in the need in intubation for 25-28 weeks gestation
![Page 5: Minimally invasive surfactant therapy in preterm](https://reader036.vdocument.in/reader036/viewer/2022081416/556c8fe9d8b42a7a738b4cf3/html5/thumbnails/5.jpg)
Outcomes for infants commencing on CPAP coud be further improved if those with significant RDS were to receive exogenous surfactant at an early stage
![Page 6: Minimally invasive surfactant therapy in preterm](https://reader036.vdocument.in/reader036/viewer/2022081416/556c8fe9d8b42a7a738b4cf3/html5/thumbnails/6.jpg)
INSURE limitations has prompted the pursuit of alternative less invasive means of giving surfactant therapy to preterm infants on CPAP
![Page 7: Minimally invasive surfactant therapy in preterm](https://reader036.vdocument.in/reader036/viewer/2022081416/556c8fe9d8b42a7a738b4cf3/html5/thumbnails/7.jpg)
MISTDirect tracheal catherizationFlexible feeding tube positioned in trachea
with Magills forceps
![Page 8: Minimally invasive surfactant therapy in preterm](https://reader036.vdocument.in/reader036/viewer/2022081416/556c8fe9d8b42a7a738b4cf3/html5/thumbnails/8.jpg)
A new alternative method of surfactant delivery via tracheal catherization using a semirigid vascular catheter
Which was found to be practicable with no significant procedural complication s
![Page 9: Minimally invasive surfactant therapy in preterm](https://reader036.vdocument.in/reader036/viewer/2022081416/556c8fe9d8b42a7a738b4cf3/html5/thumbnails/9.jpg)
aiimsTo evaluate the applicability & apparent
safety of the technique
Document the physiologic response to surfactant administration
Comare outcomes of infants receiving MIST with like gestation historical controls
![Page 10: Minimally invasive surfactant therapy in preterm](https://reader036.vdocument.in/reader036/viewer/2022081416/556c8fe9d8b42a7a738b4cf3/html5/thumbnails/10.jpg)
MethodsSite
NICU of ROYAL HOBART HOSPITAL&NICU OF ROYAL WOMEN HOSPITAL
BOTH UNITS USED cpap as initial respiratory support
![Page 11: Minimally invasive surfactant therapy in preterm](https://reader036.vdocument.in/reader036/viewer/2022081416/556c8fe9d8b42a7a738b4cf3/html5/thumbnails/11.jpg)
Study groupsInfants receiving MISTSTUDY conducted b/w june 2009-2011 may Preterm infants b/w 25 &32 completed weeks
of gestation were eligible for inclusion with CPAP &,24 hrs age required cpap pressure of ≥7
![Page 12: Minimally invasive surfactant therapy in preterm](https://reader036.vdocument.in/reader036/viewer/2022081416/556c8fe9d8b42a7a738b4cf3/html5/thumbnails/12.jpg)
Control Data were collected frm infants managed on
CPAP in time period immediately before beginning the study (2006-2009)
![Page 13: Minimally invasive surfactant therapy in preterm](https://reader036.vdocument.in/reader036/viewer/2022081416/556c8fe9d8b42a7a738b4cf3/html5/thumbnails/13.jpg)
Mist procedureSurfactant instilled via tracheal
catheterization On stable babies with HR>120 SPO2>85%A 16 gauge vascular catheter was marked to
indicate desired depth of ninsedtion (25-26 – 1cm )(27-28 wks 1.5 cm)
Direct larygoscopy performed tracheal catheter was inserted beyond vocal cords surfactant given at dose of 100 or 200 mg/kg
![Page 14: Minimally invasive surfactant therapy in preterm](https://reader036.vdocument.in/reader036/viewer/2022081416/556c8fe9d8b42a7a738b4cf3/html5/thumbnails/14.jpg)
Catheter withdrawn CPAP recommenced
Care after MIST included monitoring &treatment of PDA &screening of IVH &ROP
![Page 15: Minimally invasive surfactant therapy in preterm](https://reader036.vdocument.in/reader036/viewer/2022081416/556c8fe9d8b42a7a738b4cf3/html5/thumbnails/15.jpg)
RESULTSTOTAL 61 infants were enrolledInfants at 25-28 weeks gestation received
surfactant via MIST at early age (3hrs)Those at 29 32 weeks gestation (9hrs)
A modest decrease in CPAP pressure was notedafter MIST sustained at least 24 hrs of life
Oxygenation improved after MIST in both gestational ages with reduction in Fio2
![Page 16: Minimally invasive surfactant therapy in preterm](https://reader036.vdocument.in/reader036/viewer/2022081416/556c8fe9d8b42a7a738b4cf3/html5/thumbnails/16.jpg)
Comparedb with historical controls the need for intubation before 72h was considerably reduced after MIST in 25-28 wks
In this study the narrow bore semirigid design of catheter means that, unlike a standard endotracheal tube
![Page 17: Minimally invasive surfactant therapy in preterm](https://reader036.vdocument.in/reader036/viewer/2022081416/556c8fe9d8b42a7a738b4cf3/html5/thumbnails/17.jpg)
It can be passed down the eyeline without obscuring the view of the glottis , with an external diameter less than half that of a 2.5 mm endotracheal tube
Mist catheter passes easily through vocal cords
![Page 18: Minimally invasive surfactant therapy in preterm](https://reader036.vdocument.in/reader036/viewer/2022081416/556c8fe9d8b42a7a738b4cf3/html5/thumbnails/18.jpg)
MIST well tolerated by infants on CPAP , despite receiving no premedication
Surfactant administration via MIST was associated witha more rapid and pronounced improvement in oxygenation
![Page 19: Minimally invasive surfactant therapy in preterm](https://reader036.vdocument.in/reader036/viewer/2022081416/556c8fe9d8b42a7a738b4cf3/html5/thumbnails/19.jpg)
Based on these results large scale RCT OF MIST IS REQUIRED
![Page 20: Minimally invasive surfactant therapy in preterm](https://reader036.vdocument.in/reader036/viewer/2022081416/556c8fe9d8b42a7a738b4cf3/html5/thumbnails/20.jpg)
SURFACTANT REPLACEMENTONE OF THE BEST STUDIED THERAPIES
IN NEONATESurfactants of human,bovine or porcine
origin have been studied
![Page 21: Minimally invasive surfactant therapy in preterm](https://reader036.vdocument.in/reader036/viewer/2022081416/556c8fe9d8b42a7a738b4cf3/html5/thumbnails/21.jpg)
TimingProphylactic treatment of deficiency before
lung injury occurs ,results in better distributon and less lung injury than supplementation once respiratory failureb is severe
![Page 22: Minimally invasive surfactant therapy in preterm](https://reader036.vdocument.in/reader036/viewer/2022081416/556c8fe9d8b42a7a738b4cf3/html5/thumbnails/22.jpg)
ResponseResponse variesThe reasons include timing of treatment &
patient factors such as concurrent illness & degree of of lung maturity
Delayed resuscitationExcessive fluid administrationImproper ventilator stratagies
![Page 23: Minimally invasive surfactant therapy in preterm](https://reader036.vdocument.in/reader036/viewer/2022081416/556c8fe9d8b42a7a738b4cf3/html5/thumbnails/23.jpg)
Combined use of antenatal steroids& post natal surfactant therapy improves neonatal outcome
In established RDS repeated surfactant treatment results in greater improvement in oxygenation& ventilation decreased risk of pneumothorax & improve d survival when compared to single dose therapy
![Page 24: Minimally invasive surfactant therapy in preterm](https://reader036.vdocument.in/reader036/viewer/2022081416/556c8fe9d8b42a7a738b4cf3/html5/thumbnails/24.jpg)
retreatment infants on mechanical ventilation&Pressure >7 Fio2>0.3
![Page 25: Minimally invasive surfactant therapy in preterm](https://reader036.vdocument.in/reader036/viewer/2022081416/556c8fe9d8b42a7a738b4cf3/html5/thumbnails/25.jpg)
administrationSurvanta-beractant bovine dose 4ml/kg(100m/kg) divided in 4 quater
doses
Prophylaxis : give with in 15 min of birth in infats at risk
4 doses can be given no more frequently than every 6hrs
![Page 26: Minimally invasive surfactant therapy in preterm](https://reader036.vdocument.in/reader036/viewer/2022081416/556c8fe9d8b42a7a738b4cf3/html5/thumbnails/26.jpg)
Infasurf (calfactant)3 ml/kg for prophylaxis or rescue therapyMax 3 doses
![Page 27: Minimally invasive surfactant therapy in preterm](https://reader036.vdocument.in/reader036/viewer/2022081416/556c8fe9d8b42a7a738b4cf3/html5/thumbnails/27.jpg)
Curosurf (poractant) Intial dose 2.5 ml/kg 2 susequent doses 1.25ml/kg administered
12hrs apart
![Page 28: Minimally invasive surfactant therapy in preterm](https://reader036.vdocument.in/reader036/viewer/2022081416/556c8fe9d8b42a7a738b4cf3/html5/thumbnails/28.jpg)
complicationsPulmonary hemorrage Occurs in extremely LBW babies MalesWho have clinical evidence of PDA